Daiichi Sankyo & AstraZeneca’s Enhertu receives 2024 Prix Galien USA Award for Best Biotechnology Product: Tokyo Monday, November 11, 2024, 09:00 Hrs [IST] Daiichi Sankyo and As ...
In a move aimed at providing relief to cancer patients, the National Pharmaceutical Pricing Authority (NPPA) has directed ...
Sarah Sammons, MD, discusses findings from an analysis of the DESTINY-Breast03 trial regarding trastuzumab deruxtecan vs ...
Alteogen Inc. (KOSDAQ:196170) announced today that the company has entered into an exclusive license agreement with Daiichi Sankyo (TSE: 4568). Under the terms of the agreement, Daiichi Sankyo will ...
Alteogen Inc. said that it has entered into an exclusive license agreement with Daiichi Sankyo (DSKYF.PK). As per the terms of the ...
Researchers from the George Washington University and the Washington DC Veterans Affairs Medical Center have published a case ...
ENHERTU is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being ...
Daiichi Sankyo has signed a deal worth up to $300 million with South Korean biotech Alteogen to develop a subcutaneous ...
After chemotherapy failure, if the cancer is also resistant to endocrine therapy, patients face a double obstacle: few ...
NPPA asks companies to revise MRP of three anti-cancer drugs and submit information: Gireesh Babu, New Delhi Tuesday, October 29, 2024, 16:15 Hrs [IST] The National Pharmaceutical ...
Additionally, the study did not establish the efficacy of T-Duo in patients previously treated with trastuzumab deruxtecan. This study was supported by Byondis B.V. Co-authors Evelyn van den Tweel ...